Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report), Acrivon Therapeutics, Inc. (ACRV – Research Report) and Neurocrine (NBIX – Research Report).
Intellia Therapeutics (NTLA)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Intellia Therapeutics, with a price target of $62.00. The company’s shares closed last Thursday at $24.96, close to its 52-week low of $22.81.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $66.09, which is a 131.9% upside from current levels. In a report issued on November 2, Bank of America Securities also maintained a Buy rating on the stock with a $84.00 price target.
See the top stocks recommended by analysts >>
Acrivon Therapeutics, Inc. (ACRV)
In a report released yesterday, Etzer Darout from BMO Capital reiterated a Buy rating on Acrivon Therapeutics, Inc., with a price target of $24.00. The company’s shares closed last Thursday at $4.59.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Acrivon Therapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $24.17, representing a 342.7% upside. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.
Neurocrine (NBIX)
In a report released yesterday, Evan Seigerman from BMO Capital reiterated a Hold rating on Neurocrine, with a price target of $100.00. The company’s shares closed last Thursday at $112.15.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Neurocrine has an analyst consensus of Moderate Buy, with a price target consensus of $132.56, which is a 14.5% upside from current levels. In a report issued on October 31, Wells Fargo also maintained a Hold rating on the stock with a $110.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q3 EPS ($1.38), consensus ($1.50)
- Intellia Therapeutics Inc (NTLA) Q3 Earnings Cheat Sheet
- Intellia Therapeutics announces new interim data on NTLA-2001
- Cathie Wood’s ARK Investment bought 284K shares of Intellia Therapeutics today
